Otsuka Pharmaceutical
↗Chiyoda, Tokyo, Japan
Otsuka Pharmaceutical is a major Japanese pharmaceutical company headquartered in Chiyoda, Tokyo, established in 1964. The company operates as part of Otsuka Holdings Co., Ltd., which was founded in 1921 by Busaburo Otsuka. Otsuka is Japan's No. 2 drug maker by sales and employs over 45,000 people across 174 group companies in 28 countries worldwide. The company pursues a holistic approach to health and well-being, guided by the corporate philosophy "Otsuka-people creating new products for better health worldwide." Otsuka operates with significant presence in the United States through subsidiary companies including Otsuka America, Inc. (OAI), Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), and acquired specialty companies like Visterra, Jnana Therapeutics, and Astex Pharmaceuticals.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharma - CNS, Nephrology, Oncology
SIZE & FINANCIALS
Employees:10000+
Revenue:$15.6B+ (¥2.33 trillion in fiscal 2024)
Founded:1964
Ownership:public
Status:operating
FUNDING
Stage:N/A - Public Company
STOCK
Exchange:TSE (Tokyo Stock Exchange)
Ticker:4578
PIPELINE
Stage:Phase 1 through Commercial
Lead Drug Stage:Commercial (ABILIFY MAINTENA, REXULTI, JYNARQUE, VOYXACT)
Modalities:Small molecule, Monoclonal antibodies, Bispecific antibodies, Precision antibodies
Trial Phases:Phase 3: 5
FDA Approvals:4
CORPORATE STRUCTURE
Parent Company:Otsuka Holdings Co., Ltd.
Subsidiaries:Otsuka America, Inc. (OAI), Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Visterra, Inc. (acquired 2018, kidney disease focus), Jnana Therapeutics (acquired 2024, PKU and autoimmune focus), Astex Pharmaceuticals (acquired 2013, oncology, Cambridge UK), Otsuka Pharmaceutical Europe Ltd., Taiho Oncology Inc., Pharmavite LLC, Nardobel SAS, Korea Otsuka Pharmaceutical, 174 total group companies (36 in Japan, 138 outside Japan)
Key Partnerships:Lundbeck, Harbour BioMed, Sunovion Pharmaceuticals, Proteus Digital Health, ShapeTX
COMPETITION
Position:Leader - Japan's No. 2 pharmaceutical company by sales with strong position in CNS, nephrology, and oncology
Competitors:Takeda Pharmaceutical Company, Daiichi Sankyo, Sumitomo Pharma, AstraZeneca, Pfizer, Johnson & Johnson, Bristol Myers Squibb, Eli Lilly
LEADERSHIP
Key Executives:
Makoto Inoue - Director, President and Chief Executive Officer of Otsuka Holdings Co., Ltd.
Ichiro Otsuka - Chairman of Otsuka Holdings Co., Ltd.
Yuko Makino - Chief Financial Officer and Director
Tarek Rabah - President & CEO of Otsuka's North America Pharmaceutical Business
Scientific Founders:Busaburo Otsuka
LINKS
Website:otsuka-us.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Otsuka Pharmaceutical. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.